Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.3, Iss.9, 2008-09, pp. : 1123-1143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Small Molecule Inhibition of the Bcl-XL-BH3 Protein-Protein Interaction: Proof-of-Concept of an In Vivo Chemopotentiator ABT-737

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 10, 2007-05 ,pp. : 961-965

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of protein–protein interaction

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 9, 2002-09 ,pp. : 1453-1454

Informa Healthcare

Access to resources Recommend Favorite

Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery

Current Medicinal Chemistry, Vol. 17, Iss. 29, 2010-10 ,pp. : 3393-3409

Bentham Science Publishers

Access to resources Recommend Favorite

Target validation and drug discovery using genomic and protein–protein interaction technologies

By Pillutla Renuka C Fisher Paul B Blume Arthur J Goldstein Neil I

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 4, 2002-08 ,pp. : 517-531

Informa Healthcare

Access to resources Recommend Favorite

Protein-Protein Interaction (PPI) Network: Recent Advances in Drug Discovery

Current Drug Metabolism, Vol. 18, Iss. 1, 2017-01 ,pp. : 5-10

Bentham Science Publishers

Access to resources Recommend Favorite